Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH 1: Insulin Degludec vs Glargine in T1D
NCT02034513Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period at 16 weeks. Started Jan 2014; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02034513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034513.